Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 56

Sort by

Sort Order Select

Journal Articles

Ibromics: A Real-World Study of Clinical and Biological Parameters in Patients with Chronic Lymphocytic Leukemia (CLL) Treated in First Line with Single Agent Ibrutinib

Cecilia Muñoz-Calleja, José Ángel Hernández-Rivas, Francesc Bosch, Laura Palomo, Adrian Mosquera Orgueira, Angel Ramirez, Ruben Fernandez Alvarez, Ana C Oliveira, Paula Amat Martinez, Alicia Serrano, Aránzazu García-Grande, Ana Yeguas, Marta Crespo, Miguel Alcoceba, Blanca Ferrer Lores, José Antonio Garcia Vela, Luis Espinosa-Hevia, Celia Bolumburu, Miguel Villanueva Forero

Blood (2024) 144 (Supplement 1): 6769.

https://doi.org/10.1182/blood-2024-199097

Published: 2024

Journal Articles

First-Line Ibrutinib Plus Venetoclax Vs Chlorambucil Plus Obinutuzumab in Elderly or Comorbid Patients (Pts) with Chronic Lymphocytic Leukemia (CLL): Glow Study 64-Month Follow-up (FU) and Adverse Event (AE)-Free Progression-Free Survival (PFS) Analysis

Blood (2024) 144 (Supplement 1): 1871.

https://doi.org/10.1182/blood-2024-203269

Published: 2024

Journal Articles

Evolution of Treatment Patterns and Sequencing in Mantle Cell Lymphoma (MCL) in Spain and Their Impact on Survival. the Geltamo-MCL-2022 Study

Blood (2024) 144 (Supplement 1): 4403.

https://doi.org/10.1182/blood-2024-209936

Published: 2024

Journal Articles

Real-World Evidence of First-Line Therapy in Transplant Eligible Multiple Myeloma Patients: Insights from the Cimma Study

Maria-Victoria Mateos, Fernando Escalante, Natalia Marin Huarte, Angela Garcia Garcia-Porrero, Miguel Jesús Villanueva Forero, Rafael Rios Tamayo, Antonia Sampol Mayol, Eugenio Gimenez, Jose-Angel Hernandez Rivas, Savana Research Group, Joaquin Martinez Lopez

Blood (2024) 144 (Supplement 1): 5164.

https://doi.org/10.1182/blood-2024-205945

Published: 2024

Journal Articles

Initiating First-Line (1L) Fixed-Duration (FD) Ibrutinib and Venetoclax (Ibr+Ven) in Patients (Pts) with Chronic Lymphocytic Leukemia (CLL) Improves Overall Survival (OS) Outcomes to Rates Approximating an Age-Matched General European Population

Paolo Ghia, Loic Ysebaert, Ann Janssens, Mohamed Fouad, Claudio Schioppa, Jose-Angel Hernandez Rivas, Alessandra Tedeschi

Blood (2024) 144 (Supplement 1): 3254.

https://doi.org/10.1182/blood-2024-203883

Published: 2024

Journal Articles

Use of Post-Induction Treatment in Mantle Cell Lymphoma (MCL) in Spain. Do All Young Fit Patients Need Autologous Stem Cell Transplantation (ASCT) in the Era of High-Dose Ara-C (HiDAC) and Rituximab Maintenance ?

Blood (2024) 144 (Supplement 1): 4422.

https://doi.org/10.1182/blood-2024-211078

Published: 2024

Journal Articles

Real-World Evidence of First-Line Therapy in Non-Transplant Eligible Multiple Myeloma Patients: Insights from the Cimma Study

Blood (2024) 144 (Supplement 1): 7878.

https://doi.org/10.1182/blood-2024-206018

Published: 2024

Journal Articles

Survival Outcomes of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) Treated in the Chemoimmunotherapy Vs BTK Inhibitor (BTKi) Eras: A European Research Initiative on CLL (ERIC) Study

T C, Eva Minga, Georgios Karakatsoulis, Elisa Albi, Miguel Alcoceba, David Allsup, Francesca Bacchiarri, Sotiria Besikli-Dimou, Sofia Chatzileontiadou, Rosa Collado, Zadie Davis, Maria Dimou, David Donaldson, Maria Efstathopoulou, Sara Galimberti, Andrea Galitzia, Eva Gimeno, Valerio Guarente, Eleftheria Hatzimichael, Jose-Angel Hernandez-Rivas, Gloria Iacoboni, Iliana Konstantinou, Ioannis Kotsianidis, Jana Kotaskova, Andreas Epameinondas Koumpis, Zuzana Kubova, Jorge Labrador, Luca Laurenti, Juan Marquet, Stanislava Maslejova, Carlota Mayor-Bastida, Fatima Miras, Riccardo Moia, Almudena Navarro-Bailon, Jacopo Olivieri, Maria Papaioannou, Anna Puiggros, Gian Matteo Rigolin, Mattia Schipani, Tereza Shokralla, Martin Simkovic, Antigoni Tranidou, Theodoros Vassilakopoulos, Andrea Visentin, Candida Vitale, George Vrachiolias, Renata Walewska, Lucrecia Yanez San Segundo, Jana Zuchnicka, David Graham Oscier, Alessandro Gozzetti, Panayiotis Panayiotidis, Francesc Bosch, Paolo Sportoletti, Blanca Espinet, Gerassimos Pangalis, Maria Angelopoulou, Tomas Papajik, Roberta Murru, Marta Coscia, Antonio Cuneo, Gianluca Gaidano, Niki Stavrogianni, Livio Trentin, Lukas Smolej, Mark Caterwood, Martin Spacek, Sarka Pospisilova, Michael Doubek, Anastasia Chatzidimitriou, Kostas Stamatopoulos, Paolo Ghia, Lydia Scarfo

Blood (2024) 144 (Supplement 1): 4619.

https://doi.org/10.1182/blood-2024-202046

Published: 2024

Journal Articles

First-Line Fixed-Duration Ibrutinib Plus Venetoclax (Ibr+Ven) Versus Chlorambucil Plus Obinutuzumab (Clb+O): 55-Month Follow-up from the Glow Study

Blood (2023) 142 (Supplement 1): 634.

https://doi.org/10.1182/blood-2023-177713

Published: 2023

Journal Articles

Impact of the Current Treatments on the Survival of Patients with Mantle Cell Lymphoma (MCL): A Real-Life Study on Behalf of the Spanish Group of Lymphoma (GELTAMO)

Blood (2023) 142 (Supplement 1): 1678.

https://doi.org/10.1182/blood-2023-186101

Published: 2023

Journal Articles

Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from the EPICOVIDEHA survey

Livio Pagano, Jon Salmanton-García, Francesco Marchesi, Ola Blennow, Maria Gomes da Silva, Andreas Glenthøj, Jaap van Doesum, Yavuz M. Bilgin, Alberto López-García, Federico Itri, Raquel Nunes Rodrigues, Barbora Weinbergerová, Francesca Farina, Giulia Dragonetti, Caroline Berg Venemyr, Jens van Praet, Ozren Jaksic, Toni Valković, Iker Falces-Romero, Sonia Martín-Pérez, Moraima Jiménez, Julio Dávila-Valls, Martin Schönlein, Emanuele Ammatuna, Stef Meers, Mario Delia, Zlate Stojanoski, Anna Nordlander, Tobias Lahmer, László Imre Pinczés, Caterina Buquicchio, Klára Piukovics, Irati Ormazabal-Vélez, Nicola Fracchiolla, Michail Samarkos, Gustavo-Adolfo Méndez, José-Ángel Hernández-Rivas, Ildefonso Espigado, Martin Cernan, Verena Petzer, Sylvain Lamure, Roberta di Blasi, Joyce Marques de Almedia, Michelina Dargenio, Monika M. Biernat, Mariarita Sciumè, Cristina de Ramón, Nick de Jonge, Josip Batinić, Avinash Aujayeb, Monia Marchetti, Guillemette Fouquet, Noemí Fernández, Giovanni Zambrotta, Maria Vittoria Sacchi, Anna Guidetti, Fatih Demirkan, Lucia Prezioso, Zdeněk Ráčil, Marcio Nucci, Miloš Mladenović, Raphaël Liévin, Michaela Hanáková, Stefanie Gräfe, Uluhan Sili, Marina Machado, Chiara Cattaneo, Tatjana Adžić-Vukičević, Luisa Verga, Jorge Labrador, Laman Rahimli, Matteo Bonanni, Francesco Passamonti, Antonio Pagliuca, Paolo Corradini, Martin Hoenigl, Philipp Koehler, Alessandro Busca, Oliver A. Cornely

Blood (2022) 140 (26): 2773–2787.

https://doi.org/10.1182/blood.2022017257

Published: 2022

Includes: Supplemental data

Journal Articles

Impact of the COVID-19 Pandemic on the Incidence Registry of Hematological Neoplasms in the Region of Madrid (Spain). Preliminary Report of 2014-2021

Blood (2022) 140 (Supplement 1): 10965–10966.

https://doi.org/10.1182/blood-2022-167155

Published: 2022

Journal Articles

Ibrutinib Plus Bendamustine Plus Rituximab and Rituximab Maintenance (I+BR) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone Regimen (R-CHOP) and Rituximab, Cyclophosphamide, Doxorubicin, Bortezomib, Prednisone Regimen (VR-CAP) in First-Line Mantle Cell Lymphoma Patients: An Adjusted Treatment Comparison Using Inverse Probability Weighting

Jose Angel Hernandez-Rivas, Pier Luigi Zinzani, Mats Jerkeman, Malalatiana Be Harvel, Suzy Van Sanden, Joris Diels, Asad Husain, Christoph Tapprich, Sanjay Deshpande, Steven Le Gouill, Martin Dreyling

Blood (2022) 140 (Supplement 1): 3648–3650.

https://doi.org/10.1182/blood-2022-158259

Published: 2022

Journal Articles

Evaluation of Lenalidomide (LEN) Vs Placebo in Non-Transfusion Dependent Low Risk Del(5q) MDS Patients. Final Results of Sintra-REV Phase III International Multicenter Clinical Trial

Blood (2022) 140 (Supplement 1): 1109–1111.

https://doi.org/10.1182/blood-2022-168718

Published: 2022

Journal Articles

Long-Term Evolution of Somatic Mutations in Patients with Del(5q) MDS Early Treated with Lenalidomide in the Sintra-Rev Clinical Trial: Safe and Effecitive Approach?

Blood (2022) 140 (Supplement 1): 9740–9743.

https://doi.org/10.1182/blood-2022-168599

Published: 2022

Journal Articles

Comprehensive Geriatric Assessment Is a Useful Tool for Predicting the Outcome of Elderly Patients with Hematologic Malignancies in Real Life

Isabel González-gascón-y-Marín, Sara Martínez-Flores, Elena Landete, Elena Baeza-Monedero, María Ángeles Foncillas, Paula Fernández-Montalbán, Carolina Cecilia Muñoz-Novas, Maria Stefania Infante, Karen Marín-Mori, Juan Churruca Sarasqueta, Laura Sánchez-Paz, Victoria Ramos-de-Ascanio, Fátima Brañas, José Ángel Hernández-Rivas

Blood (2022) 140 (Supplement 1): 8105–8107.

https://doi.org/10.1182/blood-2022-159417

Published: 2022

Journal Articles

Belantamab Mafodotin in Combination with Vrd for the Treatment of Newly Diagnosed Transplant Eligible Multiple Myeloma Patients: Results from the Phase II, Open Label, Multicenter, GEM-BELA-Vrd Trial

Blood (2022) 140 (Supplement 1): 7286–7288.

https://doi.org/10.1182/blood-2022-162584

Published: 2022

Journal Articles

Immunoparesis Recovery in Transplant-Ineligible Newly Diagnosis Multiple Myeloma Patients: An Independent Prognosis Factor That Could Complement Prognostic Value of Minimal Residual Disease

Blood (2022) 140 (Supplement 1): 2344–2346.

https://doi.org/10.1182/blood-2022-166826

Published: 2022

Journal Articles

Clinical Features and Outcome of Patients with Castleman Disease Subtypes: A Spanish Multicentric Study of 145 Patients from Geltamo

Blood (2022) 140 (Supplement 1): 9342–9344.

https://doi.org/10.1182/blood-2022-163165

Published: 2022

Journal Articles

Thrombotic and Bleeding Complications in Patients with Chronic Lymphocytic Leukemia and Severe COVID-19: A Study of Eric, the European Research Initiative on CLL

Darko Antic, Natasa Milic, Thomas Chatzikonstantinou, Lydia Scarfò, Vladimir Otasevic, Nina Rajovic, David Allsup, Alejandro Alonso Cabrero, Martin Andres, Monica Baile Gonzales, Antonella Capasso, Rosa Collado, Raul Cordoba, Carolina Cuéllar-García, Juan Gonzalo Correa, Lorenzo De Paoli, Maria Rosaria De Paolis, Giovanni Del Poeta, Maria Dimou, Michael Doubek, Maria Efstathopoulou, Shaimaa El-Ashwah, Alicia Enrico, Blanca Espinet, Lucia Farina, Angela Ferrari, Myriam Foglietta, Alberto Lopez-Garcia, Jose A. Garcia-Marco, Rocío García-Serra, Massimo Gentile, Eva Gimeno, Maria Gomes da Silva, Odit Gutwein, Yervand Hakobyan, Yair Herishanu, José Ángel Hernández-Rivas, Tobias Herold, Gilad Itchaki, Ozren Jaksic, Ann Janssens, Оlga B. Kalashnikova, Elżbieta Kalicińska, Arnon P. Kater, Sabina Kersting, Maya Koren-Michowitz, Jorge Labrador Gomez, Deepesh Lad, Luca Laurenti, Alberto Fresa, Mark-David Levin, Carlota Mayor Bastida, Lara Malerba, Roberto Marasca, Monia Marchetti, Juan Marquet, Biljana Mihaljevic, Ivana Milosevic, Fatima Mirás, Marta Morawska, Marina Motta, Talha Munir, Roberta Murru, Raquel Nunes, Jacopo Olivieri, Miguel Arturo Pavlovsky, Inga S. Piskunova, Viola Maria Popov, Francesca Maria Quaglia, Giulia Quaresmini, Gianluigi Reda, Gian Matteo Rigolin, Amit Shrestha, Martin Šimkovič, Svetlana Smirnova, Martin Špaček, Paolo Sportoletti, Oana Stanca, Niki Stavroyianni, Doreen Te Raa, Kristina Tomic, Sanne Tonino, Livio Trentin, Ellen Van Der Spek, Michel van Gelder, Marzia Varettoni, Andrea Visentin, Candida Vitale, Vojin Vukovic, Ewa Wasik-Szczepanek, Tomasz Wróbel, Lucrecia Yanez San Segundo, Mohamed A Yassin, Marta Coscia, Alessandro Rambaldi, Emili Montserrat, Robin Foà, Antonio Cuneo, Marc Carrier, Paolo Ghia, Kostas Stamatopoulos

Blood (2022) 140 (Supplement 1): 2772–2775.

https://doi.org/10.1182/blood-2022-169909

Published: 2022

NARROW

Ibromics: A Real-World Study of Clinical and Biological Parameters in Patients with Chronic Lymphocytic Leukemia (CLL) Treated in First Line with Single Agent Ibrutinib

First-Line Ibrutinib Plus Venetoclax Vs Chlorambucil Plus Obinutuzumab in Elderly or Comorbid Patients (Pts) with Chronic Lymphocytic Leukemia (CLL): Glow Study 64-Month Follow-up (FU) and Adverse Event (AE)-Free Progression-Free Survival (PFS) Analysis

Evolution of Treatment Patterns and Sequencing in Mantle Cell Lymphoma (MCL) in Spain and Their Impact on Survival. the Geltamo-MCL-2022 Study

Real-World Evidence of First-Line Therapy in Transplant Eligible Multiple Myeloma Patients: Insights from the Cimma Study

Initiating First-Line (1L) Fixed-Duration (FD) Ibrutinib and Venetoclax (Ibr+Ven) in Patients (Pts) with Chronic Lymphocytic Leukemia (CLL) Improves Overall Survival (OS) Outcomes to Rates Approximating an Age-Matched General European Population

Use of Post-Induction Treatment in Mantle Cell Lymphoma (MCL) in Spain. Do All Young Fit Patients Need Autologous Stem Cell Transplantation (ASCT) in the Era of High-Dose Ara-C (HiDAC) and Rituximab Maintenance ?

Real-World Evidence of First-Line Therapy in Non-Transplant Eligible Multiple Myeloma Patients: Insights from the Cimma Study

Survival Outcomes of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) Treated in the Chemoimmunotherapy Vs BTK Inhibitor (BTKi) Eras: A European Research Initiative on CLL (ERIC) Study

First-Line Fixed-Duration Ibrutinib Plus Venetoclax (Ibr+Ven) Versus Chlorambucil Plus Obinutuzumab (Clb+O): 55-Month Follow-up from the Glow Study

Impact of the Current Treatments on the Survival of Patients with Mantle Cell Lymphoma (MCL): A Real-Life Study on Behalf of the Spanish Group of Lymphoma (GELTAMO)

Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from the EPICOVIDEHA survey

Impact of the COVID-19 Pandemic on the Incidence Registry of Hematological Neoplasms in the Region of Madrid (Spain). Preliminary Report of 2014-2021

Evaluation of Lenalidomide (LEN) Vs Placebo in Non-Transfusion Dependent Low Risk Del(5q) MDS Patients. Final Results of Sintra-REV Phase III International Multicenter Clinical Trial

Long-Term Evolution of Somatic Mutations in Patients with Del(5q) MDS Early Treated with Lenalidomide in the Sintra-Rev Clinical Trial: Safe and Effecitive Approach?

Comprehensive Geriatric Assessment Is a Useful Tool for Predicting the Outcome of Elderly Patients with Hematologic Malignancies in Real Life

Belantamab Mafodotin in Combination with Vrd for the Treatment of Newly Diagnosed Transplant Eligible Multiple Myeloma Patients: Results from the Phase II, Open Label, Multicenter, GEM-BELA-Vrd Trial

Immunoparesis Recovery in Transplant-Ineligible Newly Diagnosis Multiple Myeloma Patients: An Independent Prognosis Factor That Could Complement Prognostic Value of Minimal Residual Disease

Clinical Features and Outcome of Patients with Castleman Disease Subtypes: A Spanish Multicentric Study of 145 Patients from Geltamo

Thrombotic and Bleeding Complications in Patients with Chronic Lymphocytic Leukemia and Severe COVID-19: A Study of Eric, the European Research Initiative on CLL

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only